ArticleBMJ open2026
Association of rubella and parvovirus B19 IgM positivity and suspected rheumatoid arthritis: a retrospective analysis from a large US national reference laboratory (2014-2023).
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRubella and parvovirus B19 (B19V) infections can present with arthritis-like symptoms in adults instead of typical dermatological symptoms. We quantify associations between rubella and B19V, respectively, with arthritis-like complications using real-world diagnostic testing.
designCross-sectional and retrospective cohort study.
settingReference laboratories across the USA.
participantsParticipants with IgM tests for rubella (N=211 917) or B19V (N=644 473) performed at Labcorp from 2014 to 2023. Among these participants, participants with IgM tests for rubella (N=1867) or B19V (N=22 683) and longitudinal laboratory testing through Labcorp were followed for diagnostic tests for rheumatoid arthritis (RA) up to 1.5 years after the viral IgM tests. PRIMARY AND SECONDARY OUTCOME MEASURES: Primary outcomes were arthritis-like suspicions by providers and diagnostic testing for RA-associated biomarkers.
resultsHigher proportions of suspicions of arthritis (1.4%, p<0.001) and same-day RA-associated diagnostic testing (1.3%, p<0.001) and positivity (26.4%, p=0.003) were identified in rubella IgM-positive adults compared with rubella IgM-negative adults. A higher proportion of B19V IgM-positive adults had suspected arthritis (12.6%) compared with B19V IgM-negative adults (8.1%, p<0.001). While a higher proportion of B19V IgM-positive adults (21.3%) received RA-associated diagnostic testing compared with B19V IgM-negative adults (14.3%, p<0.001), a lower proportion of B19V IgM-positive adults with RA-associated diagnostic testing (12.8%) tested positive (B19V IgM-negative: 15.5%, p<0.001). There was a 33% increased risk of a suspected RA diagnosis in B19V IgM-positive participants compared with B19V IgM-negative participants (HR=1.33, 95% CI 1.10 to 1.61).
conclusionsIncreased awareness of non-typical RA symptoms may facilitate differential diagnosis between rubella, B19V and RA. Recent B19V infections do not occur concurrently with RA; recent B19V infections should be considered in the differential diagnosis for RA when patients present with polyarticular joint symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.